Literature DB >> 34229153

Longitudinal patterns of momentary stress during outpatient opioid agonist treatment: A growth-mixture-model approach to classifying patients.

Albert J Burgess-Hull1, Kirsten E Smith2, Destiny Schriefer2, Leigh V Panlilio2, David H Epstein2, Kenzie L Preston2.   

Abstract

BACKGROUND: We previously showed, in people starting treatment for opioid use disorder (OUD), that stress is neither necessary nor sufficient for lapses to drug use to occur, despite an association between the two. Both theoretical clarity and case-by-case prediction accuracy may require initial differentiation among patients. AIM: To examine: (a) evidence for distinct overall trajectories of momentary stress during OUD treatment, (b) relationships between stress trajectory and treatment response, and (c) relationships between stress trajectory and momentary changes in stress and craving prior to lapses.
METHODS: We used ecological momentary assessment (EMA) to collect ratings of stress and craving 3x/day for up to 16 weeks in 211 outpatients during agonist treatment for OUD. With growth mixture models, we identified trajectories of stress. We used mixed effect models to examine trajectory-group differences in the dynamics of stress and craving just before lapses to any drug use.
RESULTS: We identified four trajectories of stress: Increasing (13.7 %); Moderate and Stable (23.7 %); Declining and Increasing (18 %); and Low (44.6 %). Overall drug use and opioid craving were lowest in the Low Stress group. Overall drug use was highest in the Moderate and Stable group. Alcohol use and opioid craving were highest in the Increasing Stress group. Opioid craving increased before lapse for most groups, but stress increased before lapses for only the Moderate and Stable group.
CONCLUSION: There are natural groupings of participants with distinct patterns of stress severity during OUD treatment. Momentary stress/craving/lapse associations may be better characterized when these groupings are considered first. Published by Elsevier B.V.

Entities:  

Keywords:  Cluster analysis; Ecological momentary assessment; Growth mixture models; Individual differences; Opioid use disorder; Stress

Mesh:

Substances:

Year:  2021        PMID: 34229153      PMCID: PMC8377984          DOI: 10.1016/j.drugalcdep.2021.108884

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.852


  20 in total

1.  An acute psychosocial stressor increases drinking in non-treatment-seeking alcoholics.

Authors:  Suzanne E Thomas; Amy K Bacon; Patrick K Randall; Kathleen T Brady; Ronald E See
Journal:  Psychopharmacology (Berl)       Date:  2011-01-28       Impact factor: 4.530

2.  Negative affect and smoking lapses: a prospective analysis.

Authors:  Saul Shiffman; Andrew J Waters
Journal:  J Consult Clin Psychol       Date:  2004-04

3.  Some of the people, some of the time: field evidence for associations and dissociations between stress and drug use.

Authors:  Melody Furnari; David H Epstein; Karran A Phillips; Michelle L Jobes; William J Kowalczyk; Massoud Vahabzadeh; Jia-Ling Lin; Kenzie L Preston
Journal:  Psychopharmacology (Berl)       Date:  2015-07-09       Impact factor: 4.530

4.  Effect of stress on oral morphine and fentanyl self-administration in rats.

Authors:  Y Shaham; K Alvares; S M Nespor; N E Grunberg
Journal:  Pharmacol Biochem Behav       Date:  1992-03       Impact factor: 3.533

5.  Before and after: craving, mood, and background stress in the hours surrounding drug use and stressful events in patients with opioid-use disorder.

Authors:  Kenzie L Preston; William J Kowalczyk; Karran A Phillips; Michelle L Jobes; Massoud Vahabzadeh; Jia-Ling Lin; Mustapha Mezghanni; David H Epstein
Journal:  Psychopharmacology (Berl)       Date:  2018-07-07       Impact factor: 4.530

6.  Cognitive-behavioral intervention increases abstinence rates for depressive-history smokers.

Authors:  S M Hall; R F Muñoz; V I Reus
Journal:  J Consult Clin Psychol       Date:  1994-02

7.  Beyond abstinence and relapse II: momentary relationships between stress, craving, and lapse within clusters of patients with similar patterns of drug use.

Authors:  Leigh V Panlilio; Samuel W Stull; Jeremiah W Bertz; Albert J Burgess-Hull; Stephanie T Lanza; Brenda L Curtis; Karran A Phillips; David H Epstein; Kenzie L Preston
Journal:  Psychopharmacology (Berl)       Date:  2021-02-08       Impact factor: 4.415

Review 8.  Ambulatory Assessment Methods to Examine Momentary State-Based Predictors of Opioid Use Behaviors.

Authors:  Albert Burgess-Hull; David H Epstein
Journal:  Curr Addict Rep       Date:  2021-01-02

Review 9.  Psychological therapies for post-traumatic stress disorder and comorbid substance use disorder.

Authors:  Neil P Roberts; Pamela A Roberts; Neil Jones; Jonathan I Bisson
Journal:  Cochrane Database Syst Rev       Date:  2016-04-04

10.  Prediction of stress and drug craving ninety minutes in the future with passively collected GPS data.

Authors:  David H Epstein; Matthew Tyburski; William J Kowalczyk; Albert J Burgess-Hull; Karran A Phillips; Brenda L Curtis; Kenzie L Preston
Journal:  NPJ Digit Med       Date:  2020-03-04
View more
  3 in total

1.  Trajectories of craving during medication-assisted treatment for opioid-use disorder: Subtyping for early identification of higher risk.

Authors:  Albert J Burgess-Hull; Leigh V Panlilio; Kenzie L Preston; David H Epstein
Journal:  Drug Alcohol Depend       Date:  2022-02-18       Impact factor: 4.492

2.  Intra-individual variability and stability of affect and craving among individuals receiving medication treatment for opioid use disorder.

Authors:  Jennifer D Ellis; Chung Jung Mun; David H Epstein; Karran A Phillips; Patrick H Finan; Kenzie L Preston
Journal:  Neuropsychopharmacology       Date:  2022-06-06       Impact factor: 8.294

3.  Latent trajectories of anxiety and depressive symptoms among adults in early treatment for nonmedical opioid use.

Authors:  Jennifer D Ellis; Jill A Rabinowitz; Jonathan Wells; Fangyu Liu; Patrick H Finan; Michael D Stein; Denis G Antoine Ii; Gregory J Hobelmann; Andrew S Huhn
Journal:  J Affect Disord       Date:  2021-12-04       Impact factor: 4.839

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.